Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2003
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndromeConstance A Benson, Paige L Williams, Judith S Currier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2010
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialCharles Flexner, Camlin Tierney, Robert Gross, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
Nature Communications|April 17, 2026
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Journal of Antimicrobial Chemotherapy|February 3, 2016
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsStefanie Hennig, Elin M Svensson, Ronald Niebecker, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent modelsHenry Pertinez, Amit Kaushik, Paul Curley, et al.
JAMA|February 17, 2005
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAARTRichard E Nettles, Tara L Kieffer, Patty Kwon, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2003
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndromeConstance A Benson, Paige L Williams, Judith S Currier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2010
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialCharles Flexner, Camlin Tierney, Robert Gross, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2010
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patientsTimothy J Wilkin, Zhaohui Su, Amy Krambrink, et al.
Nature Communications|April 17, 2026
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Journal of Antimicrobial Chemotherapy|February 3, 2016
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsStefanie Hennig, Elin M Svensson, Ronald Niebecker, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent modelsHenry Pertinez, Amit Kaushik, Paul Curley, et al.
JAMA|February 17, 2005
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAARTRichard E Nettles, Tara L Kieffer, Patty Kwon, et al.
Pageof 14